Timothy E. Askew

Mr. Askew co-owns HV PharmaLabs & HV Pharmacy, Inc. (“HVP”) with Brian H. Trentler, R.Ph.  HVP is a 33-year provider of custom, branded, and generic medications to patients and physician practices in the mid-Atlantic region.  Focusing on providing custom sterile medications and biologics for ophthalmology, HVP operates as a high-quality manufacturer of customized medications and biological therapies.  HVP owns the brands NovoTears™, OP Drops™, and Stat Drops™.

Prior to HVP Mr. Askew was President/CEO of Tissue Banks International, the largest integrated ocular, musculoskeletal, and dermis processor and distributor in the world.  With over 50 owned and affiliated facilities around the world, TBI recovers, processes, and distributes a wide range of biological implants to thousands of physicians with exacting standards.  TBI works with physicians, tissue engineers, and scientists to create innovative allografts and live-cell implants for spine, orthopedic, sports medicine, dermis, and ocular applications.

Prior to TBI, Mr. Askew was President/CEO and Chairman of CSA Medical, Inc., a privately held medical device technology company dedicated to pioneering the TruFreezeTM platform to eradicate pre-cancerous and cancerous tissues.  TruFreeze is a patented treatment platform currently in use at the top cancer centers in the US.  At CSA Medical, Mr. Askew has raised over $20 million of private equity capital and led the company through numerous regulatory, clinical, product development, staffing, and commercialization milestones.   CSA Medical is currently commercializing a novel therapy to treat chronic bronchitis.

Mr. Askew is very active in the Baltimore/DC medical technology space.  He currently works with a wide range of medical device ventures in the Mid-Atlantic region, serving as in investor, board member, advisor, mentor, and consultant.

A graduate of the University of Michigan where he studied a pre-med curriculum, he received his MBA from Boston University in 1989.  Mr. Askew has published papers in Circulation-Journal of the American Heart Association and has a patent for a compound he developed along with multiple patents in process at the USPTO.

Mr. Askew also donates his time as a reviewer for the Maryland Innovation Initiative and as a member of the Coulter Foundation Oversight Committee at the Johns Hopkins University Center for Bioengineering Innovation and Design.  He is also an active member in the Central Maryland Beekeepers Association.

Brian H. Trentler, R.Ph.

Mr. Trentler has been a full-time institutional and independent pharmacist since graduating from the University Of Maryland School Of Pharmacy in 1991.

From 1991 to 1997 Mr. Trentler worked for 6 years at the Johns Hopkins Hospital in Baltimore, MD.  While at Johns Hopkins, Mr. Trentler specialized in critical care medicine, specifically general surgery, neurosurgery, and cardiac surgery.  Within each specialty, he participated in grand rounds and was a vital element of the Hopkins Medical care team.

While at Johns Hopkins, Mr. Trentler co-authored two papers: (1) Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose, and (2) Does Intraoperative Blood Loss Affect Antibiotic Serum and Tissue Concentrations?  Mr. Trentler also provided numerous nursing continuing education seminars and presented a novel antibiotic dosing strategy to the surgical intensive care unit’s resident staff.

From 1997 to 2000 Mr. Trentler became a project manager at Pfizer & Roche Diagnostics.  In this role, he worked on disease management programs designed to develop, maintain, and track clinical outcomes for patients with diabetes and depression demonstrating improved quality of life in both patient populations.

In 2001 Mr. Trentler became a Clinical Manager for CVS Caremark. In this role, he worked with Fortune 500 companies such as Proctor & Gamble, Comcast, and Wendy’s to implement employee pharmacy benefits.  This position required both quarterly and annual objectives to provide and analyze data regarding customers’ drug spending and utilization along with proactive cost containment strategies.

In 2004, Mr. Trentler became co-owner of Hunt Valley Pharmacy.  His passion is developing and introducing product and service offerings to improve customer satisfaction, health, and loyalty.  Custom compounding, the cornerstone of Hunt Valley Pharmacy’s business, has grown significantly over the past 11 years.  In 2014 Mr. Trentler partnered with Mr. Tim Askew to introduce sterile compounding to compliment successful non-sterile compounding product lines as Hunt Valley PharmaLabs.

Since 2011, Mr. Trentler has served on Maryland Medicaid’ Drug Utilization Review Board & Corrective Managed Care Advisory Committee.  The Drug Utilization Board works to optimize patient outcomes by balancing cost effective treatment modalities.  The Corrective Managed Care Advisory Committee investigates reports of fraud and abuse within Maryland Medicare programs saving taxpayer money and  ensuring integrity amongst providers.